Chromosomes Shed Light on Severe COVID-19 in Men

The XY chromosomes may potentially explain why males worldwide experience higher rates of hospitalization, ICU admission, and mortality, even though infection rates are similar between genders. While the pre-clinical study published in the journal iScience is yet to be replicated in humans, it suggests that the ACE2 protein could be a significant factor in the gender-based differences in COVID-19 outcomes. "COVID-19 severity and mortality are much higher in males than in females, but the reasons for this remain poorly understood," said Haibo Zhang, a staff scientist at St. Michael's Hospital, and a Professor of anesthesiology and pain medicine, and physiology at the University of Toronto.

Located on the cell's outer surface, ACE2 plays an important role in controlling blood pressure and inflammation and protecting organs from damage caused by excess inflammation. During a SARS-CoV-2 infection, the coronavirus spike protein locks on to ACE2 to enter the cell. The gene encoding the ACE2 protein is located on the X chromosome, which means that females have two copies of the gene and males only have one.

How Genetic Variations and Hormone Signaling Impact COVID-19 Outcomes

In times of health, the extra copy of the gene for ACE2 doesn't appear to make a difference - Zhang and his team found similar levels of ACE2 protein in healthy males and females. Following a SARS-CoV-2 infection, however, they observed a dramatic decrease in ACE2 in males while levels remained consistent in females, suggesting that the additional copy of the ACE2 gene on the X chromosome is helping to compensate and maintain high protein levels in females, the study showed. The changes in ACE2 levels were also correlated with a drop in estrogen hormone signalling in males, which could also contribute to the sex-specific differences in COVID-19 outcomes.

To test whether low levels of ACE2 were responsible for the more severe outcomes seen in males with COVID-19, the researchers devised a therapeutic approach using an inhaler to deliver lab-made ACE2 proteins directly into the lungs. Males who received a daily puff of ACE2 after SARS-CoV-2 infection had less virus in their lungs, less lung injury and higher levels of estrogen signalling. Together, these results paint a clearer picture of how the extra copy of the ACE2 gene and higher estrogen levels in females work together to protect them from experiencing more severe COVID-19, the team said.

"A common misconception is that an increased presence of ACE2 receptors would result in a higher infection rate," Zhang said. "However, the enhanced activation of ACE2 in females actually serves as a compensatory mechanism during infection that's aimed at safeguarding the lungs and other vital organs from potential damage."

As a result, there is not enough of the protein to fulfil its usual functions of tamping down inflammation and preventing organ damage. The extra dose of ACE2 delivered by inhaler serves as a decoy to glom onto the coronavirus, thereby preventing it from entering cells while also keeping the native ACE2 proteins free to exert protective effects.

Reference:

1. Inhalation of ACE2 as a therapeutic target on sex-bias differences in SARS-CoV-2 infection and variant of concern - (https://www.cell.com/iscience/fulltext/S2589-0042(23)01547-X)

Source-IANS